ABSTRACT
PURPOSE OF REVIEW: In-stent restenosis (ISR) is the most common cause of stent failure. Although the rate of ISR is significantly lower with contemporary drug-eluting stents (DES), it remains a challenging clinical entity to treat. RECENT FINDINGS: In this review, we focus on a practical approach to management of DES ISR with intravascular imaging at its core, as supported by several recently published articles. This facilitates assessment of the underlying mechanism(s) essential to the successful treatment of ISR allowing for a tailored selection of treatment modalities. SUMMARY: The successful treatment of DES ISR requires identification of the causative mechanism(s). Individualized treatment may include high-pressure balloon angioplasty alone, cutting or scoring balloons, intravascular lithotripsy, atheroablative therapies and a selection of either repeat DES implantation or drug-coated balloon treatment.
Subject(s)
Angioplasty, Balloon, Coronary , Coronary Restenosis , Drug-Eluting Stents , Percutaneous Coronary Intervention , Humans , Drug-Eluting Stents/adverse effects , Treatment Outcome , Coronary Restenosis/etiology , Coronary Restenosis/therapy , Angioplasty, Balloon, Coronary/adverse effects , Percutaneous Coronary Intervention/adverse effects , Coronary Angiography , Prosthesis DesignABSTRACT
Very short duration of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) has recently attracted a lot of attention with the introduction of newer generations stents. This is appealing, especially in patients at high bleeding risk. However, none of the trials were powered for the individual ischemic and bleeding endpoints. All randomised controlled trials (RCTs) investigating one-month versus routine duration of DAPT in patients undergoing PCI and reporting outcomes from the time of cessation of DAPT (1 month) to 1 year were eligible for inclusion in the meta-analysis. The pooled risk ratios (RR) with their 95% confidence interval (CI) were calculated with the random-effects model using the Mantel-Haenszel method. Four RCTs involving 26,576 patients were included in this meta-analysis. Cessation of DAPT after 1 month was associated with significantly less major bleeding [RR 0.70, 95%CI (0.51-0.95), P = 0.02, heterogeneity (I2) = 42%]. There was no statistically significant difference in all-cause mortality [RR 0.84 (95%CI 0.69-1.03), P = 0.10, I2 = 0%] and stroke [RR 0.71 (95%CI 0.45-1.13), P = 0.15, I2 = 42%] when compared to routine duration of DAPT. There was also no difference in myocardial infarction (MI) [RR 1.12 (95%CI 0.91-1.39), P = 0.28, I2 = 0%], and definite or probable stent thrombosis [RR 1.49 (95%CI 0.92-2.41), P = 0.11, I2 = 0%] with cessation of DAPT after 1 month. Cessation of DAPT 1 month after PCI was associated with significantly less major bleeding, but there was no difference in the rate of all-cause mortality, stroke, MI and stent thrombosis.
Subject(s)
Percutaneous Coronary Intervention , Platelet Aggregation Inhibitors , Humans , Drug Therapy, Combination , Hemorrhage/chemically induced , Myocardial Infarction , Platelet Aggregation Inhibitors/adverse effects , Randomized Controlled Trials as Topic , Stroke/diagnosis , Stroke/etiology , Stroke/prevention & control , Thrombosis/prevention & control , Thrombosis/chemically induced , Treatment OutcomeABSTRACT
Facilitated antegrade dissection re-entry (F-ADR) is a technique described for treating post coronary artery bypass surgery chronic total occlusions (CTO) when there is flush occlusion of the distal cap of the CTO at the vein graft anastomosis. In this scenario retrograde access is usually impossible and if antegrade wiring fails, F-ADR is then the best option. Following antegrade dissection past the anastomosis, a balloon is delivered via the vein graft and inflated in the native vessel distal to the anastomosis to facilitate re-entry using a Stingray catheter. However, the applicability and outcome of this technique have not been described in cases where the graft to native vessel anastomosis has previously been stented. We report a case series of successful CTO recanalization using F-ADR across stented graft-native vessel anastomoses.
Subject(s)
Coronary Occlusion , Percutaneous Coronary Intervention , Skates, Fish , Animals , Humans , Coronary Occlusion/diagnostic imaging , Coronary Occlusion/surgery , Coronary Angiography , Percutaneous Coronary Intervention/methods , Feasibility Studies , Treatment Outcome , Chronic DiseaseABSTRACT
OBJECTIVE: The aim of the review was to assess whether CHA2DS2-VASc score is predictive of mortality in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). BACKGROUND: The CHA2DS2-VASc score is validated in predicting stroke risk in atrial fibrillation. The optimum management strategy for these patients undergoing PCI is still debated. METHODS: The CHA2DS2-VASc score was calculated in consecutive patients with atrial fibrillation undergoing PCI in a large Australian registry between 2007 and 2013. Patients were divided into low (1-2), intermediate (3-4) and high (≥5) groups. Clinical and procedural data, 30-day, 1-year and long-term outcomes were compared between the groups. RESULTS: A total of 564 patients were included in our analysis. Patients with high CHA2DS2-VASc scores had higher mortality rates at 1-year (2, 8, 15; P = 0.002) and long-term (6, 20, 37; P < 0.001). High-risk patients were more likely to have renal impairment and multivessel disease. Increasing CHA2DS2-VASc score was associated with increased risk of stroke (0, 2, 6; P = 0.03). However, only 41.9% received anticoagulation, with no difference across the risk groups. When compared to low-risk, intermediate [HR 3.57; 95% confidence interval (CI), 1.28-9.92; P = 0.015] and high (hazard ratio 7.82; 95% CI, 2.88-21.24; P < 0.001) CHA2DS2-VASc scores were significant predictors of long-term mortality. CONCLUSIONS: Higher CHA2DS2-VASc scores in patients with atrial fibrillation undergoing PCI are associated with significantly worse outcomes. Despite being high-risk, the patients in this cohort are likely undertreated with anticoagulation. Close clinical follow-up with greater utilization of anticoagulation and optimal medical therapy has the potential to improve long-term outcomes.
Subject(s)
Atrial Fibrillation/mortality , Atrial Fibrillation/therapy , Percutaneous Coronary Intervention , Risk Assessment , Aged , Australia/epidemiology , Female , Humans , Male , Middle Aged , Organ Dysfunction Scores , Registries , Stroke/epidemiologyABSTRACT
BACKGROUND: Poly ADP-ribose polymerase (PARP) inhibitors target pathogenic BRCA mutations in chemotherapy-resistant malignancies. PARP inhibitors cause modest dose-dependent QT prolongation in the setting of a normal baseline QT interval. CASE SUMMARY: We describe a case of PARP inhibitor-induced torsades de pointes (TdP) in an 86-year-old gentleman prescribed rucaparib due to chemotherapy-resistant, metastatic prostate cancer with pre-existing long QT, with an apparent dose-dependent increase in QT interval. The patient presented with syncope and recurrent TdP requiring direct cardioversion reversion (200 J biphasic) and an isoprenaline infusion (2 µg/min). There were no other QT prolonging agents and no electrolyte or metabolic disturbance to account for this arrhythmia. Improvement in QT interval was observed within 72 h of rucaparib cessation. DISCUSSION: PARP inhibitors cause a modest, dose-dependent increase in QT interval in patients with a normal baseline. The safety of PARP inhibitors in patients with pre-existing long QT has not been evaluated. This is the first reported case of rucaparib-associated TdP in a patient with pre-existing long QT, highlighting the amplified effect of this agent in individuals with pre-existing QT prolongation and the risk of fatal arrhythmias.
ABSTRACT
The aim of this study was to determine if serum C-reactive protein (CRP), an acute phase reactant which exhibits a rapid rise in serum in inflammatory conditions, is a reliable predictor of abdomino-pelvic CT findings in the clinical setting of the non-traumatic acute abdomen. All patients presenting with symptoms of acute abdominal pain to a level-1 emergency department over a 12-month period were included. Patients with serum CRP measured on admission and within 24 h of the abdomino-pelvic CT scan were subselected and those with a history of recent surgery, malignancy, and inflammatory bowel disease were excluded (n = 241). CT findings were graded in consensus by two radiologists and visceral adipose volume and severity of adipose stranding were also assessed. Statistical analysis was performed using SPSS v17. Positive imaging findings were evident on 176 CTs (73 %). There were equal numbers of positive and negative CT scans in patients with low serum level of CRP (0-5 mg/L). As CRP level increased the proportion of positive CTs increased (p < 0.001, Chi-square test for trend). The likelihood ratio for positive CT findings in patients with a CRP level greater than 130 mg/L was 3.45 with reported specificity and sensitivity of 90.9 and 31.4 %, respectively. A low CRP level (0-5 mg/L) does not out rule positive findings on CT in the clinical setting of the acute abdomen. Increasing levels of CRP predict, with increasing likelihood, positive findings on CT.